Lagercrantz - No Sign of Cost Increases or Shortages
2022-02-08 09:45:00
Redeye raises its Base Case in Lagercrantz following a solid Q3 report and increased assumptions for future M&A. There are no signs of cost increases or shortages on the group level, highlighting Lagercrantz’s ability to handle externalities.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/